All In Biotech

Drug Trial Radar · NCT01297920

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,062 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,062

Actual

Start

Mar 2011

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Feb 17, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.

Conditions

  • Open-Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensionDrug

  • Brinzolamide ophthalmic suspension, 1%Drug

  • Brimonidine tartrate ophthalmic solution, 0.2%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3Time frame: Month 3

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.